{"id":"duloxetine-hydrochloride-hci","safety":{"commonSideEffects":[{"rate":"20-25","effect":"Nausea"},{"rate":"10-15","effect":"Dizziness"},{"rate":"10-12","effect":"Somnolence"},{"rate":"10-15","effect":"Dry mouth"},{"rate":"8-10","effect":"Fatigue"},{"rate":"8-10","effect":"Constipation"},{"rate":"5-8","effect":"Decreased appetite"},{"rate":"5-8","effect":"Sweating"}]},"_chembl":{"chemblId":"CHEMBL1200328","moleculeType":"Small molecule","molecularWeight":"333.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the reuptake transporters for both serotonin and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This dual mechanism is thought to enhance mood regulation and pain signaling modulation. The drug is used to treat depression, anxiety disorders, and chronic pain conditions including diabetic peripheral neuropathic pain and fibromyalgia.","oneSentence":"Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:12.762Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Diabetic peripheral neuropathic pain"},{"name":"Fibromyalgia"},{"name":"Chronic musculoskeletal pain"}]},"trialDetails":[{"nctId":"NCT00755807","phase":"PHASE3","title":"Duloxetine for Multiple Sclerosis Pain","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-10","conditions":"Multiple Sclerosis","enrollment":239}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY248686","Cymbalta"],"phase":"phase_3","status":"active","brandName":"Duloxetine Hydrochloride (HCI)","genericName":"Duloxetine Hydrochloride (HCI)","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites. Used for Major depressive disorder, Generalized anxiety disorder, Diabetic peripheral neuropathic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}